Cargando…

Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers

The development of immune checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed cell death protein ligand 1 (PD-L1) has revolutionized the treatment strategy in various types of cancers. In addition, recent studies hav...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eso, Yuji, Seno, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443993/ https://www.ncbi.nlm.nih.gov/pubmed/32913444 http://dx.doi.org/10.1177/1756284820948773

Ejemplares similares

Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers
por: Eso, Yuji, et al.
Publicado: (2019)

Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers
por: Kim, Bum Jun, et al.
Publicado: (2017)

Hepatobiliary and pancreatic surgery in the elderly: Current status
por: Papis, Davide, et al.
Publicado: (2020)

Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary–pancreatic cancers
por: Ozono, Yoshinori, et al.
Publicado: (2023)

Review of Current Applications of Immunohistochemistry in Pediatric Nonneoplastic Gastrointestinal, Hepatobiliary, and Pancreatic Lesions
por: de Nanassy, Joseph, et al.
Publicado: (2017)

Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms
por: Miljanic, Mihailo, et al.
Publicado: (2020)

Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers
por: Marin, Jose J. G., et al.
Publicado: (2022)

Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer
por: Lim, Sung Won, et al.
Publicado: (2019)

Current Immune Checkpoint Inhibitor Genetic Biomarker Exploration in Gastrointestinal Tumors
por: Rogers, Jane E., et al.
Publicado: (2022)

Gastrointestinal, hepatobiliary, and pancreatic manifestations of COVID-19
por: Patel, Kishan P., et al.
Publicado: (2020)

The Role of Immune Checkpoint Inhibitors in Metastatic Pancreatic Cancer: Current State and Outlook
por: Tran, Linh Chi, et al.
Publicado: (2023)

Hereditary Pancreatic and Hepatobiliary Cancers
por: Haddad, Ashraf, et al.
Publicado: (2011)

Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers
por: Li, Meng, et al.
Publicado: (2022)

Laparoscopic hepatobiliary and pancreatic surgery: my trials and current status in Korea
por: Yun, Sung Su
Publicado: (2021)

Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers
por: Saoudi González, Nadia, et al.
Publicado: (2022)

Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies
por: Mazloom, Anita, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update
por: DeCarli, Kathryn, et al.
Publicado: (2022)

COVID-19: gastrointestinal and hepatobiliary manifestations()()
por: Shih, Angela R., et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives
por: Federico, Piera, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches
por: Batista-Duharte, Alexander, et al.
Publicado: (2022)

The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity
por: Xing, Hui, et al.
Publicado: (2023)

Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
por: Xiong, Wei, et al.
Publicado: (2021)

Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer
por: Kang, Byung Woog, et al.
Publicado: (2020)

Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors
por: Grywalska, Ewelina, et al.
Publicado: (2019)

Utility of KRAS mutational analysis in the preoperative diagnosis of synchronous pancreatic cancer and intrahepatic cholangiocarcinoma: A case report
por: Eso, Yuji, et al.
Publicado: (2017)

Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers
por: Hochnadel, Inga, et al.
Publicado: (2017)

The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review
por: Brahm, Cyrillo G., et al.
Publicado: (2020)

Recent Advances in Immunotherapy for Hepatocellular Carcinoma
por: Nakano, Shigeharu, et al.
Publicado: (2020)

Genetic Landscape of Multistep Hepatocarcinogenesis
por: Takeda, Haruhiko, et al.
Publicado: (2022)

Immune checkpoint inhibitors in cervical cancer: Current status and research progress
por: Xie, Yunkai, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective
por: Lavacchi, Daniele, et al.
Publicado: (2020)

Current Treatments of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitors—2020 Update
por: Jung, Gerhard, et al.
Publicado: (2020)

Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer
por: Kudo-Saito, Chie, et al.
Publicado: (2022)

Current progress in robotic hepatobiliary and pancreatic surgery at a high‐volume center
por: McCarron, Frances N., et al.
Publicado: (2023)

Hepatobiliary and pancreatic ascariasis
por: Khuroo, Mohammad S, et al.
Publicado: (2016)

Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers
por: Yang, Xu, et al.
Publicado: (2021)

MicroRNAs in Hepatobiliary and Pancreatic Cancers
por: Saito, Yoshimasa, et al.
Publicado: (2011)

Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
por: Lopez-Beltran, Antonio, et al.
Publicado: (2021)

Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy
por: Rajha, Eva, et al.
Publicado: (2019)

Impact of Patient Characteristics on the Outcomes of Patients with Gastrointestinal Cancers Treated with Immune Checkpoint Inhibitors
por: Ohm, Hyejee, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qm2757ljog4bl40ovigka2q2vj